|
|
||||||||
RESEARCH AND PRACTICE |
Margaret E. Bentley is with the Carolina Population Center, University of North Carolina, Chapel Hill, NC. Andrew M. Fullem is with John Snow Inc, Boston, Mass. Elizabeth E. Tolley is with Family Health International, Durham, NC. Clifton W. Kelly is with the Fred Hutchinson Cancer Center, Seattle, Wash. Neelam Jogelkar is with the National AIDS Research Institute, Pune, India. Namtip Srirak is with the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand. Liness Mwafulirwa is with the Johns Hopkins University College of Medicine Research Project, Blantyre, Malawi. Gertrude KhumaloSakutukwa is with the Center for AIDS Prevention, University of California, San Francisco. David D. Celentano is with the Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Md.
Correspondence: Requests for reprints should be sent to Margaret E. Bentley, Carolina Population Center Department of Nutrition, 123 West Franklin St, Suite 308B, Chapel Hill, NC 27516 (e-mail: pbentley{at}unc.edu).
Objectives. We analyzed qualitative and quantitative data for 98 HIV-negative, low-risk women in Malawi, Zimbabwe, India, and Thailand who participated in a safety and acceptability study of BufferGel, a vaginal microbicide to determine the across-country acceptability of vaginal microbicides among women and their partners.
Methods. Quantitative survey data were collected at 7 and 14 days after use among enrolled women, and exit interviews were conducted with women and their partners in separate focus group discussions.
Results. Acceptability was high in all sites (73% of women approved of the microbicide). Women in Africa, where HIV infection rates are highest, were virtually unanimous in their desire for such a product, suggesting that an individuals perception of being at risk for HIV will outweigh concerns about side effects, problems applying a product, or other factors, when products are shown to be efficacious. But men and women reported that use, which was kept secret from an intimate partner, would be difficult and might "break the trust" of a relationship.
Conclusions. Acceptability research across diverse settings through all stages of microbicide research, development, and postlicensure dissemination can help maximize acceptability and use.
Related articles in AJPH:
This article has been cited by other articles:
![]() |
J. A. Higgins and J. S. Hirsch Pleasure, Power, and Inequality: Incorporating Sexuality Into Research on Contraceptive Use Am J Public Health, October 1, 2008; 98(10): 1803 - 1813. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J. Wood, P. Rizzo-Price, J. Holden, A. Hardick, T. C. Quinn, and C. A. Gaydos The Microbicide Tenofovir Does Not Inhibit Nucleic Acid Amplification Tests for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in Urine Samples J. Clin. Microbiol., February 1, 2008; 46(2): 763 - 765. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. E. Tolley and L. J. Severy Integrating Behavioral and Social Science Research Into Microbicide Clinical Trials: Challenges and Opportunities Am J Public Health, January 1, 2006; 96(1): 79 - 83. [Abstract] [Full Text] [PDF] |
||||
![]() |
Minerva BMJ, July 24, 2004; 329(7459): 240 - 240. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |